Royalty Pharma (NASDAQ: RPRX) net income
Royalty Pharma reported a net profit of $770.9m for fiscal 2025, 10.2% less than in fiscal 2024 ($859.0m). Its net margin was 32.4%. Earnings per share were $1.79.
Royalty Pharma's net income has fallen for 2 years in a row, and its best year of the last 7 was fiscal 2019. The biggest drop was in fiscal 2022, −93.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $770.9m | −10.2% | 32.4% | $1.79 |
| 2024 | $859.0m | −24.3% | 37.9% | $1.92 |
| 2023 | $1,135m | +2,549.5% | 48.2% | $2.54 |
| 2022 | $42.8m | −93.1% | 1.9% | $0.10 |
| 2021 | $619.7m | −36.4% | 27.1% | $1.49 |
| 2020 | $975.0m | −58.5% | 45.9% | $1.32 |
| 2019 | $2,349m | — | 129.4% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Royalty Pharma net income compared with its sector
By net income for its latest fiscal year, Royalty Pharma ranks 50th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Royalty Pharma, 32.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 48th | Exelixis | $782.6m | 33.7% |
| 49th | Steris | $782.3m | 13.2% |
| 50th | Royalty Pharma | $770.9m | 32.4% |
| 51st | BIO-RAD Laboratories | $759.9m | 29.4% |
| 52nd | DaVita | $746.8m | 5.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Royalty Pharma
- How much did Royalty Pharma earn in fiscal 2025?
- Royalty Pharma reported a net profit of $770.9m for fiscal 2025. In fiscal 2024 it reported a net profit of $859.0m.
- What are the earnings per share of Royalty Pharma?
- They were $1.79 in fiscal 2025, compared with $1.92 in fiscal 2024.
- What is the net margin of Royalty Pharma?
- In fiscal 2025 its net profit was 32.4% of its revenue.
- What was the most profitable year for Royalty Pharma?
- Of its last 7 fiscal years, fiscal 2019, with $2,349m.
- Where does Royalty Pharma rank in its sector by net income?
- It ranks 50th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Royalty Pharma come from?
- From the annual report (Form 10-K) that Royalty Pharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Royalty Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Royalty Pharma: the Royalty Pharma page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.